Telomir Pharmaceuticals, Inc. Common Stock
TELO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $2,235 | $1,574 | $833 | $126 |
| G&A Expenses | $9,636 | $600 | $21 | $12 |
| SG&A Expenses | $9,636 | $600 | $21 | $12 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $371 | $1,768 | $0 | $0 |
| Operating Expenses | $12,242 | $3,942 | $854 | $138 |
| Operating Income | -$12,242 | -$3,942 | -$854 | -$138 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$4,291 | -$9,130 | $0 | $0 |
| Pre-Tax Income | -$16,533 | -$13,072 | -$854 | -$138 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$16,533 | -$13,072 | -$854 | -$138 |
| % Margin | – | – | – | – |
| EPS | -0.56 | -0.44 | -0.029 | -0.005 |
| % Growth | -27.3% | -1,427.8% | -512.8% | – |
| EPS Diluted | -0.56 | -0.44 | -0.029 | -0.005 |
| Weighted Avg Shares Out | 29,539 | 29,610 | 29,610 | 29,610 |
| Weighted Avg Shares Out Dil | 29,539 | 29,610 | 29,610 | 29,610 |
| Supplemental Information | – | – | – | – |
| Interest Income | $48 | $0 | $0 | $0 |
| Interest Expense | -$4,339 | $1,643 | $0 | $0 |
| Depreciation & Amortization | $12,242 | $0 | $854 | $138 |
| EBITDA | $48 | -$11,429 | $0 | $0 |
| % Margin | – | – | – | – |